chrisvoncsefalvay/vaers-outcomes huggingface dataset:
diarrhea; fever; sneezing; headache; coughing; felt weak; exhausted; This is a spontaneous report from a contactable consumer or other non-healthcare professional (patient) via Pfizer Sponsored Program.  A male patient (age 53 units unspecified) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 05Feb2021 as dose number unknown, single for covid-19 immunisation. Patients relevant medical history and concomitant medications were not reported. On 06Feb2021, the patient experienced coughing and felt weak. On 07Feb2021, the patient experienced sneezing and headache. On 08Feb2021, the patient experienced diarrhea and fever. On an unspecified date in Feb2021 the patient was exhausted. It was reported that the patient received Pfizer vaccine on Friday and wanted to know if his symptoms were communicable. He was experiencing sneezing, headache, coughing, diarrhea and fever. He enquired if he got tested, would he get a false positive. It was reported that patient received the Covid-19 Vaccine on Friday and reported that he is sneezing, headache, coughing, diarrhea, and fever. The patient clarified that on Saturday (06Feb2021) he felt weak and stayed in bed. On Sunday (07Feb2021) he started having a headache and some sneezing. He said that Monday (08Feb2021) he had diarrhea and was feverish. He said that he was basically exhausted. The patient said that the diarrhea only lasted a day to a day and a half. He said that he ate peanut butter and it seemed to resolve. Patient said that he wants to make certain that he was not putting his fellow workers at risk since he has these symptoms. He said that it feels like a flu or stomach flu, mild case. He said that it could possible be a adverse reaction, but he does not know.  He said he does not want to get anyone sick. Patient asked does this mean he temporarily has a communicable disease. The outcome of the events sneezing, fever, felt weak, headache and coughing was not recovered. The outcome of the event diarrhea was recovered on an unspecified date in Feb2021. The outcome of the event exhausted was unknown.  Follow-up attempts completed. No further information expected.
Narrative: COVID infection after completion of COVID vaccine series: 01/18/2021 COVID vaccine dose#1 02/09/2021 COVID vaccine dose #2 07/11/2021 Pt presented to ED c/o cough, fever, and myalgia, since 07/10/2021. 07/11/2021 COVID positive per nasopharyngeal swab 07/11/2021 Pt discharged since could manage self-care at home. Prescribed  budesonide and prednisone. 07/12/2021 Pt reported continuing to experience cough, fever, myalgia. Onset of fatigue. 07/13/2021 Pt reported continuing to experience cough, fatigue. Onset of SOB upon exertion. 07/14/2021 Pt reported improvement in symptoms.
12/22/21: Pt admitted to the ED with COVID home management. symptom onset 12/20 and positive test 12/21. Started to run a 105F fever and severe body aches. She took tylenol at 2AM. also states that she having HA, runny nose, cough, sore throat, and nausea. Denies CP or SOB. Received decadron due to hypoxia. Singulair at night. Combivent, pulmicort, and albuterol prn. Started Remdesivir (normal kidney and liver function, within 7 days onset). receiving O2 by NC 12/24-25: continue remdesivir and decadron. continue pulmicort and combivent. will see if we can wean oxygen as tolerated  12/26: general pain treated with tylenol#4 x2 and tordol x1, seemed to improve pain. O2 sats wnl on room air 12/27: Pt discharged. Completed remdesivir course. Was discharged home on pulmicort and decadron for 5 more days.
Pt taken to hospital after mom noted that site of injection was red, inflamed (hot to touch). Pt evaluated by pediatrician who diagnosed patient with cellulitis. Pt also found to have rash to chest. Pt had no fever, seizure or problems breathing. Inflammation at injection site - 9.5 cm by 8 cm. Pt sent home  with topical rx. Pt has f/u appt with pediatrician 08/27/02.
Mild fever of 100.5. Treated with Tylenol. Fever gone by 3/17.
Information has been received from a physician concerning a 13 year old female who on 30-JUL-2007 was vaccinated with 0.5 mL of varicella virus vaccine live (Oka/Merck). Concomitant therapy that same day included human papillomavirus vaccine. On 30-JUL-2007, one half hour after receiving both varicella virus and human papillomavirus vaccine, the patient broke out in hives. Unspecified medical attention was sought. There was no product quality complaint. No lot numbers provided. Additional information has been requested.
tested positive for covid on binax rapid antigen test 8/10/2023- is up to date with covid vax having received 4 doses of Moderna plus a 5th dose of bivalent
Pt vaccinated w/DTP/HIB developed high pitched screaming & inconsolable crying 4JAN91- 4PM - 830PM. Complete recovery. (This was a telephone call-child was not seen).
Swelling and pain right arm, 8x4cm induration, lymphadenopathy left axilla, pain with movement of arm
Same symptoms as when I had COVID-19 in December:  Massive headache, nausea, fatigue.  It lasted 48 hours.  intensity did not decrease with Tylenol or sleep.
Profuse bleeding from injection point, Swelling under the skin due to blood accumulation, ie. blood blister.
Back pain/pain in back; Intervertebral disc disorder/disc messed up in back; Sickness; Pain legs; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Back pain/pain in back), INTERVERTEBRAL DISC DISORDER (Intervertebral disc disorder/disc messed up in back), ILLNESS (Sickness) and PAIN IN EXTREMITY (Pain legs) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced BACK PAIN (Back pain/pain in back), INTERVERTEBRAL DISC DISORDER (Intervertebral disc disorder/disc messed up in back), ILLNESS (Sickness) and PAIN IN EXTREMITY (Pain legs). At the time of the report, BACK PAIN (Back pain/pain in back), INTERVERTEBRAL DISC DISORDER (Intervertebral disc disorder/disc messed up in back) and PAIN IN EXTREMITY (Pain legs) had not resolved and ILLNESS (Sickness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment drugs were reported.   The reporter's causality for the event(s) of pain in back, pain in legs, sick and disc messed up in back was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Feverish feeling but NO fever.  Generalized body aches (flu-like). Weak.  Headache.  Sleeplessness.  Injection site soreness.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in an 18-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Aug-2021 at 12:49 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 26-Aug-2021 at 12:49 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 26-Aug-2021 at 12:49 PM, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment information was not provided.
I felt like I got the flu. Had a running nose, felt aches and joint pains along with a fever. It lasted seven days.
This spontaneous report as received from a physician refers to an unspecified number of patients of unknown age. On an unknown dates, the patient were vaccinated with improperly stored (Oka/Merck) PROQUAD (lot # M002055, expiration 11-JUL-2017) and ZOSTAVAX, (lot # M015926, expiration date 28-JUN-2017). Temperature was 13.9 degrees F. Time frame was one hour. No adverse effects were reported. Additional information has been requested.
Approximately 10 days after my first dose (5/28/21) my arm (around the injection site) got very red, hot to the touch and sore; bad at first but subsided the next day.  HOURS after my second dose on 7/2/21 the same thing started.  It is now 3 days later and it is still, red, hot and sore but the pain isn?t as bad as it was initially.
Rash on face - red, dry patches, some bumps, itching,burning Treated with topical antihistamine
Mom contacted Physician's office to notify us that patient had redness and swelling at injection site on Left Deltoid. Mom brought patient in to Physician's office to been seen.
Gentle coughing. Little tightness in chest; went away Nov. 10, 2021 at 06:00 am.
Registered Nurse Registered Nurse Progress Notes Signed Encounter Date:  10/31/2019     Signed        Patient comes to the department with pain in her arm post influenza vaccine.  Patient state the pains runs from her left deltoid muscle down to her wrist.  She state it is a 5/10 all the time.  With certain movements it will increase to a 8 or 9/10 with certain movements.  Patient was encourage to take ibuprofen and to apply heat as needed.
VERY BAD REACTION; This spontaneous report received from a health care professional concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included: covid, and concurrent conditions included: diabetes, and cancer, and other pre-existing medical conditions included: Patient was a nurse. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 04-JUL-2022 for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced very bad reaction. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from very bad reaction. This report was non-serious.
Pt felt dizzy after receiving his vaccine. While walking towards the observation room accompanied by father and vaccinator nurse patient had a fainting episode. He was lowered to the ground by nurse/father and an assessment performed.  VS within normal limits Fainting episode lasted a few seconds. Pt reported no medical conditions or hx of fainting . Pt also mentioned  he hadn't eaten anything before receiving his vaccine.  Vitals signs as follows: BP at  0830  110/55, HR 60, O2: 96%,  at 0837: BP 107/58, HR 69, O2 97%. Pt observed for approximately 25 minutes and discharged home in stable condition accompanied by his father.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In 2016, the patient was inoculated by a pharmacist with the ZOSTAVAX (lot number, dosage and route of administration not provided) to obtain permanent prevention and protection against shingles and zoster related injuries. On or about 04-JAN-2017, the patient was treated by a physician for herpes zoster meningitis. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Upon internal review, herpes zoster meningitis was determined to be medically significant. Additional information has been requested.
did antibody testing had none; This spontaneous case was reported by a consumer and describes the occurrence of ANTIBODY TEST NEGATIVE (did antibody testing had none) in an 88-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 030L20A) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included APIXABAN (ELIQUIS), GLIMEPIRIDE, DEXLANSOPRAZOLE (DEXILANT), ATORVASTATIN, LISINOPRIL, METOPROLOL, FEXOFENADINE HYDROCHLORIDE (ALLEGRA), TRIAMCINOLONE ACETONIDE (NASACORT), GLUCOSAMINE and ASCORBIC ACID, TOCOPHERYL ACETATE, XANTOFYL, ZEAXANTHIN, ZINC (AREDS) for an unknown indication.   On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ANTIBODY TEST NEGATIVE (did antibody testing had none). At the time of the report, ANTIBODY TEST NEGATIVE (did antibody testing had none) outcome was unknown.            No treatment information was provided Action taken with mRNA-1273 in response to the events were Not Applicable
Information has been received from a registered nurse concerning an 8 year old female with no known drug allergies, who, on 18-NOV-1998, was vaccinated subcutaneously in the left arm with a dose of Varivax. There was no concomitant medication. On 15-SEP-2006 the patient presented to the doctor's office with varicella 10 to 20 lesions, clear pustules, no fever. Patient outcome was not reported. No further information is available.
Malaise, headache, generalized aching beginning on 5/20 Continual achiness and fatigue throughout this time
Day 3: slight swelling at site,red and itchy, low grade fever and diarrhea. Day 4,5,6,7,8: increased swelling and redness at site,hot to touch, persistant low grade fever and diarrhea. Day 9:Severe swelling at site, hot to touch,severe pain in arm and lymph nodes of underarm and left side of neck, fever of 101.4,pt sent to ER and diagnosed with skin infection,sent home with rx for Keflex 500mg
Could not reach vaccination report page so am reporting here. After receiving the flu shot I began itching all over to the point that it was very irritating. I then began to feel small bumps appearing. I never had a reaction in previous years. I decided to carefully read information that was given at pharmacy and found there may or may not be latex in shot. I do have a latex allergy. I had entered my food and medicine allergies on preadministration paper but did not consider latex would be in shot and was not asked if I was allergic to this. I was able to catch this quickly enough that several days of an antihistamine resolved itching. The actual spt where shot was given also remained red and raised much longer than others who received shot.
Headache; body aches; lymphatic swelling in armpit; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), MYALGIA (body aches) and LYMPHADENOPATHY (lymphatic swelling in armpit) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033b21a) for COVID-19 vaccination.     born with MRKH, only 1 kidney, allergic to cotton wood trees.  Concurrent medical conditions included Mullerian agenesis (only 1 kidney) and Allergy NOS.    On 18-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jun-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced LYMPHADENOPATHY (lymphatic swelling in armpit). On 19-Jun-2021, the patient experienced HEADACHE (Headache) and MYALGIA (body aches). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) ongoing since an unknown date for Myalgia, at an unspecified dose and frequency. On 19-Jun-2021, MYALGIA (body aches) had resolved. On 20-Jun-2021, HEADACHE (Headache) had resolved. At the time of the report, LYMPHADENOPATHY (lymphatic swelling in armpit) had not resolved.            No concomitant medication  information was provided by the reporter.
4/28 Day 6 serious numbness in right leg, glute to heel, especially in calf and heel.
ringing in the ear; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (ringing in the ear) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Not provided) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TINNITUS (ringing in the ear). At the time of the report, TINNITUS (ringing in the ear) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was reported.
Patient shaky nervous at time of injection. Nervous/shaky immediately following injection. Became pale, EMT called as precaution, vitals stable, however tongue appeared swollen, negative hives, negative lungs, negative vitals. Pt transported to hospital as precaution. Pt received SOLUMEDROL 125mg IV x 1 and sent home with BENADRYL 1 PO for any symptoms. Patient reports no further symptoms. Please document seasonal flu vaccine allergy.
This spontaneous report was received from a physician 40-year-old female patient. The patient's medical history included shingles and post herpetic neuralgia. Approximately on an unknown date (reported as a year ago) in February 2012, the patient was vaccinated with a dose of live ZOSTAVAX (lot#, expiration date and route not reported), subcutaneously after recovering from a case of shingles. The physician added that the patient's post-herpetic neuralgia resolved after she received live ZOSTAVAX. The patient was experiencing intense burning pain in left scapula region approximately on an unknown date in February 2013 (reported as 'now') which the physician had diagnosed as possible shingles. There were no lesions. The reported event had not resolved. The patient sought medical attention by office visit. Causality was not reported. Additional information is not expected.
Body aches; Fatigue; Abdominal pain; Gas; Loose stool; She was sweaty; Sore throat; Fever; This spontaneous case was reported by a nurse and describes the occurrence of HYPERHIDROSIS (She was sweaty), OROPHARYNGEAL PAIN (Sore throat), ABDOMINAL PAIN (Abdominal pain), FLATULENCE (Gas) and DIARRHOEA (Loose stool) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Dental treatment NOS (Patient had a dental procedure and received an injection of numbing agent.).    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2021, the patient experienced HYPERHIDROSIS (She was sweaty), OROPHARYNGEAL PAIN (Sore throat) and PYREXIA (Fever). On 08-Jan-2021, the patient experienced ABDOMINAL PAIN (Abdominal pain), FLATULENCE (Gas) and DIARRHOEA (Loose stool). On 09-Jan-2021, the patient experienced PAIN (Body aches) and FATIGUE (Fatigue). On 08-Jan-2021, HYPERHIDROSIS (She was sweaty), OROPHARYNGEAL PAIN (Sore throat), ABDOMINAL PAIN (Abdominal pain), FLATULENCE (Gas), DIARRHOEA (Loose stool) and PYREXIA (Fever) had resolved. At the time of the report, PAIN (Body aches) and FATIGUE (Fatigue) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient was administered expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20-2A) for COVID-19 vaccination.     Concurrent medical conditions included Type 2 diabetes mellitus since 28-Jul-2020, Congestive heart failure since 23-Mar-2020, COPD (COPD with Asthma) since 23-Mar-2020, Asthma (COPD with Asthma) since 23-Mar-2020, Chronic back pain (Chronic Lower Back Pain) since 20-Jun-2013 and BPH since 27-Aug-2013. Concomitant products included TAMSULOSIN HYDROCHLORIDE (FLOMAX [TAMSULOSIN HYDROCHLORIDE]) from 28-Mar-2021 to an unknown date for BPH, FUROSEMIDE (LASIX [FUROSEMIDE]) from 26-Oct-2020 to an unknown date, SPIRONOLACTONE (ALDACTONE [SPIRONOLACTONE]) from 26-Jun-2020 to an unknown date and APIXABAN (ELIQUIS) from 26-Mar-2020 to an unknown date for Congestive heart failure.    On 16-Mar-2021 at 10:54 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021 at 10:54 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine). On 16-Mar-2021 at 10:54 AM, EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Patient was administered expired vaccine) to be not related.    No treatment medication were reported.
This case was reported by a pharmacist via call center representative and described the occurrence of general body pain in a 51-year-old female patient who received SHINGRIX for prophylaxis. In August 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced general body pain, chills, injection site erythema and injection site warmth. On an unknown date, the outcome of the general body pain, chills, injection site erythema and injection site warmth were recovered/resolved. It was unknown if the reporter considered the general body pain, chills, injection site erythema and injection site warmth to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX on the left arm. The patient experienced little redness and heat at the injection site redness, injection site warmth. The patient had chills and body aches for 1 day. The call was transferred to Medical Information. The reporter gave consent to follow up. For tolerance of 2nd dose, refer case: US2019GSK022646, reported by the same reporter.
Pain in left arm at the injection site began at 8 hours after injection.  Chills the next morning.  Elevated temperature of 99.6 degrees F after 24 hours from injection.